Effect of bupropion on depression symptoms in a smoking cessation clinical trial

Caryn Lerman, Ray Niaura, Bradley N. Collins, Paul Wileyto, Janet Audrain-McGovern, Angela Pinto, Larry Hawk, Leonard H. Epstein

Research output: Contribution to journalArticlepeer-review


Bupropion is an antidepressant shown to be efficacious for smoking cessation. This study examined the short- and long-term effects of bupropion (300 mg/day for 10 weeks) versus placebo on depression symptoms among 497 smokers attempting to quit in a randomized trial of bupropion plus behavioral counseling. Depression symptoms were assessed via the Center for Epidemiological Studies Depression Scale (L. Radloff, 1977) at baseline, end of treatment, and at 6-month follow-up. Baseline nicotine dependence level was assessed with the Fagerström Test for Nicotine Dependence (T. F. Heatherton, L. T. Kozlowski, R. C. Frecker, & K. O. Fagerström, 1991). A regression model of depression symptoms demonstrated a significant interaction between nicotine dependence and treatment for the treatment phase and during follow-up. Depression symptoms did not mediate the effects of bupropion on abstinence at either time point. Highly nicotine-dependent smokers who receive bupropion are more likely to experience a decrease in depressive symptoms during active treatment but are also more likely to experience a rebound in depressive symptoms when bupropion is discontinued.

Original languageEnglish (US)
Pages (from-to)362-366
Number of pages5
JournalPsychology of Addictive Behaviors
Issue number4
StatePublished - Dec 2004

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health


Dive into the research topics of 'Effect of bupropion on depression symptoms in a smoking cessation clinical trial'. Together they form a unique fingerprint.

Cite this